CD274 and neoplasm: In clinical studies, PD‐L1 immunohistochemistry (IHC) and tumour mutation burden (TMB) have been the predominant predictive biomarkers explored to date; however, PD‐L1 IHC remains the dominant companion diagnostic test used in clinical practice to inform immune checkpoint inhibitor (CI) therapy.